The fastest-growing and largest of the 20 sized Pharmaceuticals markets in Mexico, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $554 Mn | $5.2 Bn | 25.2% | 61 |
| 2 | Cell Based Immunotherapy | $249 Mn | $2 Bn | 23.3% | 542 |
| 3 | Cannabidiol (CBD) | $331 Mn | $1.6 Bn | 17.1% | 0 |
| 4 | Cannabis | $509 Mn | $1.8 Bn | 13.8% | 3 |
| 5 | Atopic Dermatitis Drugs | $168 Mn | $545 Mn | 12.5% | 12 |
| 6 | Oncology/Cancer Drugs | $2.7 Bn | $6.1 Bn | 8.7% | 593 |
| 7 | Anti-Aging | $1.3 Bn | $3 Bn | 8.4% | 17 |
| 8 | Diabetes Management | $1.2 Bn | $2.4 Bn | 7.4% | 65 |
| 9 | Alzheimer Drugs | $75 Mn | $149 Mn | 7.1% | 12 |
| 10 | Contraceptives Drugs | $378 Mn | $747 Mn | 7.1% | 0 |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $2.7 Bn | $6.1 Bn | 8.7% | 593 |
| 2 | Anti-Aging | $1.3 Bn | $3 Bn | 8.4% | 17 |
| 3 | Diabetes Management | $1.2 Bn | $2.4 Bn | 7.4% | 65 |
| 4 | Gastrointestinal Drugs | $810 Mn | $1.3 Bn | 4.9% | 137 |
| 5 | Asthma & COPD Drugs | $743 Mn | $1.1 Bn | 4.3% | 23 |
| 6 | Biosimilars | $554 Mn | $5.2 Bn | 25.2% | 61 |
| 7 | Cannabis | $509 Mn | $1.8 Bn | 13.8% | 3 |
| 8 | HIV Drugs | $450 Mn | $810 Mn | 6.1% | 21 |
| 9 | Contraceptives Drugs | $378 Mn | $747 Mn | 7.1% | 0 |
| 10 | Cancer Supportive Care Drugs | $372 Mn | $603 Mn | 5% | 88 |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 25.2% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (23.3%).
Oncology/Cancer Drugs is the largest, worth about $2.7 Bn in 2023 and $6.1 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.